VRPX Virpax Pharmaceuticals Inc.

5
-0.64  -11%
Previous Close 5.63
Open 5.51
52 Week Low 4.87
52 Week High 8.24
Market Cap $24,725,765
Shares 4,945,153
Float 2,178,716
Enterprise Value $29,892,059
Volume 83,018
Av. Daily Volume 0
Stock charts supplied by TradingView

Latest News

  1. WEST CHESTER, PA / ACCESSWIRE / March 2, 2021 / Virpax® Pharmaceuticals Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing pharmaceutical products for pain management, today announced that the United States Patent and Trademark Office issued US Patent No. 10842745 entitled, "Composition of matter comprising liposome embedded in a polymerix matrix and methods of using same."

    This newly issued patent, which is owned by LipoCure Rx and exclusively licensed to Virpax, has 18 claims and expires in 2029. The patent covers a liposomal composition containing bupivacaine as well as additional claims covering methods for providing analgesia in patients by administration of the liposomal compositions.

    "We are extremely pleased…

    WEST CHESTER, PA / ACCESSWIRE / March 2, 2021 / Virpax® Pharmaceuticals Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing pharmaceutical products for pain management, today announced that the United States Patent and Trademark Office issued US Patent No. 10842745 entitled, "Composition of matter comprising liposome embedded in a polymerix matrix and methods of using same."

    This newly issued patent, which is owned by LipoCure Rx and exclusively licensed to Virpax, has 18 claims and expires in 2029. The patent covers a liposomal composition containing bupivacaine as well as additional claims covering methods for providing analgesia in patients by administration of the liposomal compositions.

    "We are extremely pleased with the continued development of the patent portfolio for ProbudurTM, our long-acting anesthetic for postoperative pain management. This newly issued patent further broadens our overall intellectual property portfolio," stated Anthony Mack, Chairman and CEO of Virpax.

    About Virpax Pharmaceuticals

    Virpax is developing branded, non-addictive pain management products candidates using its proprietary technologies to optimize and target drug delivery. Virpax is initially seeking FDA approval using its three patented drug delivery platforms. Epoladerm™ is a topical diclofenac metered-dose spray film formulation being developed to manage acute musculoskeletal pain and osteoarthritis. Probudur™ is a single injection liposomal bupivacaine formulation being developed to manage post-operative pain. Envelta™ is an intranasal molecular-envelope enkephalin formulation being developed to manage acute and chronic pain, including pain associated with cancer. Virpax is also using its intranasal Molecular Envelope Technology (MET) to develop its PES200 product candidate to manage post-traumatic stress disorder (PTSD) and its MMS019 product candidate to inhibit viral replication caused by influenza or SARS-CoV-2. For more information, please visit www.virpaxpharma.com.

    Forward-Looking Statement

    This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's planned clinical trials, product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.

    These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors, including the potential impact of the recent COVID-19 pandemic and the potential impact of sustained social distancing efforts, on the Company's operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

    Contact:

    Christopher M. Chipman, CPA
    Chief Financial Officer

    484-880-4588

    Or

    Betsy Brod
    Affinity Growth Advisors

    212-661-2231

    SOURCE: Virpax Pharmaceuticals



    View source version on accesswire.com:
    https://www.accesswire.com/632558/Virpax-Pharmaceuticals-Announces-Newly-Issued-Patent-for-ProbudurTM

    View Full Article Hide Full Article
  2. LONDON, UK / ACCESSWIRE / March 1, 2021 / Nanomerics Ltd., a world leader in molecular engineered delivery technologies, today announced that the Company had received its first milestone payments from Virpax Pharmaceuticals (NASDAQ:VRPX).

    These milestone payments relate to the licensing of Envelta™ for the treatment of non-cancer pain and MMS019, an anti-viral nasal spray. Under the terms of the license agreements Virpax Pharmaceuticals is responsible for the clinical development of Envelta™ in non-cancer pain patients and MMS019 for the prevention of respiratory viral infections, including SARS-COV-2. Virpax is developing Envelta™ under a cooperative research and development agreement with the United States National Center for Advancing Translational…

    LONDON, UK / ACCESSWIRE / March 1, 2021 / Nanomerics Ltd., a world leader in molecular engineered delivery technologies, today announced that the Company had received its first milestone payments from Virpax Pharmaceuticals (NASDAQ:VRPX).

    These milestone payments relate to the licensing of Envelta™ for the treatment of non-cancer pain and MMS019, an anti-viral nasal spray. Under the terms of the license agreements Virpax Pharmaceuticals is responsible for the clinical development of Envelta™ in non-cancer pain patients and MMS019 for the prevention of respiratory viral infections, including SARS-COV-2. Virpax is developing Envelta™ under a cooperative research and development agreement with the United States National Center for Advancing Translational Sciences (NCATS), an institute of the U.S. National Institutes of Health (NIH).

    "We are pleased that following Virpax Pharmaceuticals' initial public offering, Virpax Pharmaceuticals are now in a position to make these milestone payments, further their own development programmes and that the milestone payments will enable us to take our internal programmes towards the clinic," says Professor Andreas G. Schätzlein, Chief Executive Officer of Nanomerics. "We know, in the context of the current opioid crisis, that new pain treatments are needed and that Envelta™, which is based on enkephalin, shows good activity in all preclinical pain models; and has a potentially good safety profile."

    Professor Schätzlein also says that, "MMS019, an antiviral nasal spray, being developed to reduce transmission of respiratory viral infections, shows good anti-viral activity against SARS-COV-2 in three dimensional human airway epithelial cell cultures. (Bioarxiv preprint)"

    Anthony Mack, Chief Executive Officer of Virpax Pharmaceuticals says, "Virpax Pharmaceuticals was founded to provide innovative healthcare solutions to patients, where there is a clear unmet clinical need. We are pleased that our collaboration with Nanomerics is allowing us to fulfil our objectives in the area of pain as well as viral infection."

    About Nanomerics

    Nanomerics Ltd is a speciality pharmaceutical company based in London, UK. Nanomerics is a world leader in molecular engineered delivery technologies. Nanomerics creates uniquely differentiated, patented pharmaceutical assets, underpinned by high quality science. Nanomerics' proprietary technology is based on world leading know-how and scientific leadership in polymer engineering. For example, the company's Molecular Envelope (MET) is a unique patented biocompatible polymer that delivers a step change in target tissue bioavailability.

    The founding scientists Professor Ijeoma F. Uchegbu and Professor Andreas G. Schätzlein developed the technology at the Universities of Strathclyde and Glasgow and, latterly at the UCL School of Pharmacy. Nanomerics was spun out of University College London, a top 10 global university and was founded to commercialise its biocompatible polymer technologies for drug delivery and other applications. Envelta™ and MMS019 are one of a number of pharmaceutical product candidates that have been out-licensed by Nanomerics. Other pharmaceutical product candidates in development include NM134 for the treatment of allergic conjunctivitis and NM137 for the treatment of posterior uveitis. For more information please visit www.nanomerics.com.

    About Virpax Pharmaceuticals

    Virpax is developing branded, non-addictive pain management product candidates using its proprietary technologies to optimize and target drug delivery. Virpax is initially seeking FDA approval using its three patented drug delivery platforms; one of which is Envelta™. Envelta™ is an intranasal molecular-envelope enkephalin formulation being developed to manage acute and chronic pain, including pain associated with cancer. Virpax is also using its intranasal Molecular Envelope Technology (MET) to develop its PES200 product candidate to manage post-traumatic stress disorder (PTSD) and its MMS019 product candidate to inhibit viral replication caused by influenza or SARS-CoV-2. For more information, please visit www.virpaxpharma.com.

    Forward-Looking Statements

    This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Nanomerics cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. Forward-looking statements reflect our analysis only on their stated date, and Nanomerics takes no obligation to update or revise these statements except as may be required by law.

    For more information, please visit www.nanomerics.com or contact Nanomerics investor relations at .

    SOURCE: Nanomerics Ltd.



    View source version on accesswire.com:
    https://www.accesswire.com/632531/Double-Milestone-Payment-Strengthens-Nanomerics-Balance-Sheet-and-Enables-Nanomerics-to-Further-Clinical-Programmes

    View Full Article Hide Full Article
  3. WEST CHESTER, PA / ACCESSWIRE / February 23, 2021 / Virpax® Pharmaceuticals Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), today announced that according to the Cooperative Research and Development Agreement ("CRADA") entered into between Virpax and the National Center for Advancing Translational Sciences ("NCATS"), an institute/center of the National Institutes of Health ("NIH"), U.S. Department of Health and Human Services, the NCATS has begun the Investigational New Drug ("IND") enabling studies of Envelta™ for Virpax to support Virpax's future application for clearance from the FDA to initiate its first-in-human ("FIH") clinical trials.

    Anthony P. Mack, Chairman and CEO of Virpax stated, "The commencement of these critical pre-clinical studies…

    WEST CHESTER, PA / ACCESSWIRE / February 23, 2021 / Virpax® Pharmaceuticals Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), today announced that according to the Cooperative Research and Development Agreement ("CRADA") entered into between Virpax and the National Center for Advancing Translational Sciences ("NCATS"), an institute/center of the National Institutes of Health ("NIH"), U.S. Department of Health and Human Services, the NCATS has begun the Investigational New Drug ("IND") enabling studies of Envelta™ for Virpax to support Virpax's future application for clearance from the FDA to initiate its first-in-human ("FIH") clinical trials.

    Anthony P. Mack, Chairman and CEO of Virpax stated, "The commencement of these critical pre-clinical studies takes us one step closer to the clinic. Dr. Jeffrey Gudin, principal investigator and co-founder of Virpax, has been working in partnership with the NCATS since we announced the CRADA in August 2020. We believe that the NIH/NCATS collaborative agreement will facilitate maintaining momentum for our team in both our pre-clinical and future clinical development strategies."

    Envelta™ is an intranasal enkephalin drug product candidate formulation based on nanotechnology which enables the delivery of the drug product to the brain. Enkephalin is a naturally occurring (endogenous) peptide that is not easily administered in its original form. Envelta™ is an investigational formulation delivered via the nasal route with the potential to improve enkephalin transport to the brain. Envelta™ uses a preassembled device and cartridge to propel the enkephalin formulation through the nose to the brain by flowing along the olfactory nerve pathway. The Molecular Envelope Technology is designed to protect and help carry the drug to the brain, crossing the blood brain barrier and suppressing pain by binding to the delta-opioid receptors. Envelta™ has demonstrated analgesic potential in animal models without developing opioid tolerance, withdrawal, respiratory depression, euphoria, or addiction associated with the use of opioids.

    About Virpax Pharmaceuticals

    Virpax is developing branded, non-addictive pain management products candidates using its proprietary technologies to optimize and target drug delivery. Virpax is initially seeking FDA approval using its three patented drug delivery platforms. Epoladerm™ is a topical diclofenac metered-dose spray film formulation being developed to manage acute musculoskeletal pain and osteoarthritis. Probudur™ is a single injection liposomal bupivacaine formulation being developed to manage post-operative pain. Envelta™ is an intranasal molecular-envelope enkephalin formulation being developed to manage acute and chronic pain, including pain associated with cancer. Virpax is also using its intranasal Molecular Envelope Technology (MET) to develop its PES200 product candidate to manage post-traumatic stress disorder (PTSD) and its MMS019 product candidate to inhibit viral replication caused by influenza or SARS-CoV-2. For more information, please visit www.virpaxpharma.com.

    Forward-Looking Statement

    This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's planned clinical trials, product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.

    These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors, including the potential impact of the recent COVID-19 pandemic and the potential impact of sustained social distancing efforts, on the Company's operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

    Contact:

    Christopher M. Chipman, CPA
    Chief Financial Officer

    484-880-4588

    Or

    Betsy Brod
    Affinity Growth Advisors

    212-661-2231

    SOURCE: Virpax Pharmaceuticals



    View source version on accesswire.com:
    https://www.accesswire.com/631208/Virpax-Begins-IND-Enabling-Studies-of-EnveltaTM

    View Full Article Hide Full Article
  4. WEST CHESTER, PA / ACCESSWIRE / February 19, 2021 / Virpax Pharmaceuticals Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing pharmaceutical products for pain management, today announced the closing of its initial public offering of 1,800,000 shares of its common stock at a public offering price of $10.00 per share, for gross proceeds of $18.0 million, before deducting underwriting discounts and offering expenses. In addition, Virpax has granted the underwriters a 30-day option to purchase up to an additional 270,000 shares of common stock to cover over-allotments at the initial public offering price, less the underwriting discount.

    The Company intends to use substantially all of the net proceeds from the offering…

    WEST CHESTER, PA / ACCESSWIRE / February 19, 2021 / Virpax Pharmaceuticals Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing pharmaceutical products for pain management, today announced the closing of its initial public offering of 1,800,000 shares of its common stock at a public offering price of $10.00 per share, for gross proceeds of $18.0 million, before deducting underwriting discounts and offering expenses. In addition, Virpax has granted the underwriters a 30-day option to purchase up to an additional 270,000 shares of common stock to cover over-allotments at the initial public offering price, less the underwriting discount.

    The Company intends to use substantially all of the net proceeds from the offering to fund research and development of its Epoladerm™, Probudur™, Envelta™ and MMS019 indications and other development programs, and for working capital and other general corporate purposes.

    ThinkEquity, a division of Fordham Financial Management, Inc., acted as sole book-running manager for the offering.

    A registration statement on Form S-1 (File No. 333-249417) was filed with the Securities and Exchange Commission ("SEC"), which became effective on February 16, 2021, and the related registration statement on Form S-1 (File No. 333-253176), was filed with the SEC under Rule 462(b) of the Securities Act of 1933, as amended, relating to the shares of common stock being offered. This offering is being made only by means of a prospectus. Copies of the final prospectus may be obtained from ThinkEquity, a division of Fordham Financial Management, Inc., 17 State Street, 22nd Floor, New York, New York 10004, by telephone at (877) 436-3673, by email at . The final prospectus will be filed with the SEC and will be available on the SEC's website located at http://www.sec.gov.

    This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

    About Virpax Pharmaceuticals

    Virpax is a preclinical stage biopharmaceutical company focused on becoming a global leader in pain management by developing and delivering innovative non-opioid and non-addictive pharmaceutical products using new drug delivery systems and technology. Virpax is developing branded pharmaceutical product candidates for pain management by using advanced technology in an effort to enhance patients' quality of life. For more information, please visit www.virpaxpharma.com.

    Forward Looking Statements

    This press release contains certain forward-looking statements, including those relating to the regarding the anticipated timing of completion of the offering and other statements that are predictive in nature. Forward-looking statements are based on the Company's current expectations and assumptions. The Private Securities Litigation Reform Act of 1995 provides a safe-harbor for forward-looking statements. These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this presentation. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in the Company's filings with the Securities and Exchange Commission, including its registration statement on Form S-1, as amended from time to time, under the caption "Risk Factors."

    Contact:

    Christopher M. Chipman, CPA
    Chief Financial Officer

    484-880-4588

    Or

    Betsy Brod
    Affinity Growth Advisors

    212-661-2231

    SOURCE: Virpax Pharmaceuticals



    View source version on accesswire.com:
    https://www.accesswire.com/630659/Virpax-Pharmaceuticals-Announces-Closing-of-Initial-Public-Offering

    View Full Article Hide Full Article
View All Virpax Pharmaceuticals Inc. News